Comparative Pharmacology
Head-to-head clinical analysis: CORGARD versus INDERIDE LA 120 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORGARD versus INDERIDE LA 120 50.
CORGARD vs INDERIDE LA 120/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic receptor antagonist; competitively blocks beta1- and beta2-adrenergic receptors, leading to decreased heart rate, myocardial contractility, and blood pressure. Also prolongs sinoatrial node refractory period and inhibits renin release.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
40 mg orally once daily for hypertension; initial dose 40 mg once daily for angina, titrate up to 80-240 mg once daily. Maximum dose 320 mg/day.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
None Documented
None Documented
Terminal elimination half-life: 20-24 hours (may extend to 40 hours in renal impairment). Clinical context: Allows once-daily dosing; steady-state achieved in 5-7 days.
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Renal (unchanged, ~85-90%); fecal (<5%); biliary (<2%).
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Category C
Category C
Beta-Blocker
Beta-Blocker/Diuretic Combination